<DOC>
	<DOC>NCT02627300</DOC>
	<brief_summary>Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2 years is reached (whichever occurs first).</brief_summary>
	<brief_title>Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial</brief_title>
	<detailed_description>The study is a prospective, open-label, non-controlled, single-arm, multicentre phase III study. Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2 years is reached (whichever occurs first).</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1. Completion of the main study SCGAM 01, with good tolerance of octanorm (as determined by the investigator). 2. For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with local requirements. 3. For female patients of childbearing potential, a negative result in a urine pregnancy test conducted at the Screening visit. 4. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study. 1. Subject being without any IgG treatment for period greater than 5 weeks between the last infusion of octanorm in the SCGAM 01 study and the first infusion of octanorm in the SCGAM03 study. 2. Administration of any immunoglobulin infusion other than octanorm between conclusion of the SCGAM 01 study and the beginning of the present study. [Note: This exclusion criterion does not apply to patients who complete the SCGAM 01 study before treatment commences in the present study.] 3. Planned pregnancy during the course of the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PID</keyword>
</DOC>